{"nctId":"NCT00316914","briefTitle":"Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery","startDateStruct":{"date":"2006-01"},"conditions":["Colorectal Cancer","Neurotoxicity"],"count":104,"armGroups":[{"label":"Ca/Mg","type":"EXPERIMENTAL","interventionNames":["Drug: calcium gluconate","Drug: magnesium sulfate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"calcium gluconate","otherNames":[]},{"name":"magnesium sulfate","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the colon or rectum\n\n  * Stage II disease\n  * Stage III disease\n  * Stage IV disease (completely resected with no evidence of residual tumor)\n* Must have undergone curative resection for stage II or III disease\n* Scheduled to receive 6 months of adjuvant treatment with either of the following FOLFOX chemotherapy regimens:\n\n  * FOLFOX4, comprising leucovorin calcium, fluorouracil, and oxaliplatin (2-week course)\n  * Modified FOLFOX6, comprising high-dose leucovorin calcium, high-dose fluorouracil, and oxaliplatin (2-week course)\n\nPATIENT CHARACTERISTICS:\n\n* Absolute neutrophil count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin ≥ 10 g/dL\n* WBC ≥ 3,000/mm\\^3\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* Creatinine ≤ 1.5 times ULN\n* Calcium normal\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No pre-existing peripheral neuropathy of any grade\n* No hypercalcemia\n* No concurrent heart block or a history of heart block\n* No other medical condition that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient\n* No family history of a genetic/familial neuropathy\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior treatment with neurotoxic chemotherapy such as oxaliplatin, cisplatin, taxanes, or vinca alkaloids\n* Concurrent use of bevacizumab or cetuximab in combination with FOLFOX as part of a clinical trial or clinical practice are allowed\n* No concurrent digitalis medication\n* No concurrent digoxin\n* No concurrent treatment with anticonvulsants such as carbamazepine, phenytoin, or valproic acid\n* No other concurrent neurotropic agents such as gabapentin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event","description":"Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Grade 2+ Chronic Neurotoxicity","description":"Neurotoxicity were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"18.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Grade 3+ Chronic Neurotoxicity","description":"Neurotoxicity was assessed by CTCAE v3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Duration of Chronic Neuropathic Toxicity","description":"Neuropathic adverse events were assessed by CTCAE v3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Discontinuing Therapy for Chronic Neurotoxicity","description":"Neurotoxicity were assessed by CTCAE v3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"55.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Cumulative Oxaliplatin Dose","description":null,"classes":[]},{"type":"SECONDARY","title":"Average Duration of Oxaliplatin-containing Treatment","description":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Patients With Acute Neuropathic Adverse Event","description":"Acute neuropathic toxicities were measured using the Symptom Experience Diary and supplemental quality of life questions in the scale of 0 (no symptom) to 10 (worst symptom). The item score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Any score greater than 0 was considered having acute neuropathy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Calcium Magnesium (CaMg)-Induced Adverse Event","description":"Adverse Events were measured using CTCAE V3.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing Impact on Activities of Daily Living (ADL)","description":"Activities of daily living were measured using the Symptom Experience Diary and supplemental quality of life questions. The questionnaires' items were in the scale of 0 (no symptom) to 10 (worst symptom).","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Fatigue Score at One Month","description":"Fatigue was measured by Brief Fatigue Inventory in the scale of 0 (no fatigue) to 10 (fatigue as bad as you can imagine). The item score was reversed and transformed into 0 (low quality of life (QOL)) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"14.96"},{"groupId":"OG001","value":"-2.8","spread":"17.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"15.38"},{"groupId":"OG001","value":"-1.6","spread":"12.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"21.38"},{"groupId":"OG001","value":"-1.6","spread":"18.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QOL) at One Month","description":"Quality of Life (QOL) were measured using the Symptom Experience Diary and supplemental quality of life questions. Item score range: 0 (no symptom) to 10 (worst symptom). The score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"21.38"},{"groupId":"OG001","value":"-1.6","spread":"18.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"11.54"},{"groupId":"OG001","value":"0.2","spread":"12.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"9.27"},{"groupId":"OG001","value":"0.4","spread":"21.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"18.43"},{"groupId":"OG001","value":"-10.4","spread":"21.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"14.87"},{"groupId":"OG001","value":"0.4","spread":"26.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"11.75"},{"groupId":"OG001","value":"1.3","spread":"23.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"18.06"},{"groupId":"OG001","value":"-9.1","spread":"19.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"7.16"},{"groupId":"OG001","value":"2.1","spread":"22.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"17.56"},{"groupId":"OG001","value":"2.1","spread":"21.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"16.49"},{"groupId":"OG001","value":"-9.6","spread":"15.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.8","spread":"21.65"},{"groupId":"OG001","value":"-20.4","spread":"20.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":50},"commonTop":["Diarrhea","Nausea","Constipation","Vomiting","Neutrophil count decreased"]}}}